Palivizumab for the prevention of respiratory syncytial virus (RSV) in premature infants
Phase of Trial: Phase III
Latest Information Update: 07 May 2013
At a glance
- Drugs Palivizumab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms IMpact-RSV
- 07 May 2013 Results presented at the 2013 Annual Meeting of the Pediatric Academic Societies.
- 05 Nov 2010 New trial record.